Plerixafor as a CXCR4 inhibitor has been in clinical use in anticancer therapy for over ten years now, with approval for Non-Hodgin ́s lymphoma, but also with promising experimental results for several other solid tumors such as thyroid cancer, pleural mesothelioma, or ovarian cancer [94]. The gene discussed is CXCR4; the disease is thyroid gland carcinoma.